Biopharma stocks gained 9.6% in 2024, trailing the S&P 500’s 28.5% rise. Eli Lilly projects double-digit revenue growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback